Articles tagged with Cancer Cells
Researchers at Hebrew University discovered that insufficient building blocks in cancer cells lead to DNA damage. External supply of DNA building blocks can reactivate normal DNA synthesis and reduce cancerous features.
Researchers discovered that lopinavir selectively kills HPV-infected non-cancerous cells while leaving healthy cells relatively unaffected. The study suggests a potential treatment for HPV-related cervical cancer using locally applied lopinavir cream or pessary.
Researchers have found that over-expression of motor protein km23-1 can block human ovarian tumor growth, leading to eventual cancer cell death. This discovery offers promise for new therapies to treat ovarian cancer, a disease affecting U.S. women with an estimated 21,880 new cases and 13,850 deaths in 2010.
Cancer cells survive by ignoring signals to become senescent and continuing to make copies of themselves at will. Researchers discovered a molecular switch required for entry into quiescence and senescence, which may provide new targets for cancer treatment and help develop neurons in infants with Down syndrome.
A study by Fred Hutchinson Cancer Center researchers reveals a signaling protein called Reelin helps brain cells navigate during development. This finding may hold clues to understanding how cancer cells migrate within the body.
Researchers at the Salk Institute have uncovered a new structural beacon, called the C-tail, which is found in half of all telomeres in alternative lengthening of telomeres (ALT) tumors. This unique feature may be a key to understanding cancer cell immortality and developing effective treatments.
Researchers discovered a worm protein controlling growth factor secretion, which is linked to human cancers. The study proposes that abnormal growth factor secretion may stimulate cancer formation and offers a potential targeted treatment approach.
Researchers have created nanoparticles that can store large amounts of drugs, allowing for a millionfold increase in efficiency over comparable methods. The 'protocells' can target specific cancer cells while restricting toxic chemotherapy drugs from leaking into the system, mitigating side effects.
Researchers at The Wistar Institute have identified a connection between Merlin and angiomotin, two proteins involved in cell signaling pathways. This discovery may lead to a new therapeutic approach for NF2 by targeting tumor cells directly and starving them of nutrients.
Researchers at UT Southwestern Medical Center found that Klotho, an anti-aging hormone, suppresses renal fibrosis and cancer growth in mice. This discovery offers a potential new treatment for patients with chronic kidney disease and acute kidney injury.
The TET1 enzyme controls gene activity during fetal development, preventing genes from being turned off at critical stages. By modifying methyl groups, TET1 acts as a safeguard to ensure normal cell growth and development.
Researchers study sea squirts' simple body structure to unravel complex mechanisms of heart formation, shedding light on GATA's role in congenital heart defects. Disrupting GATA function independently in the developing gut preserves heart cell identity, while disrupting it in heart precursor cells causes limbo-like state.
A Wayne State University study found that soy isoflavones can sensitize cancer cells to radiation while protecting normal tissue. The study demonstrated that soy isoflavones can block DNA repair mechanisms in cancer cells, leading to increased killing of lung cancer cells by radiation
Researchers unveiled groundbreaking cellular analysis tools, drug-delivery methods, and novel approaches to high-throughput drug discovery. The session highlighted advances in imaging and simultaneous identification of biological compounds, as well as the use of peptides as potential drugs and biological probes.
Scientists at the University of Hull have identified a cellular mechanism controlling tissue factor inclusion in endothelial microparticles, which may help treat cardiovascular disease and cancer. The on-off switch, involving tandem amino acids, regulates phosphate molecule addition to control tissue factor release.
Researchers from UPCI and Pitt will present over 80 posters, talks, and tutorials on various cancer studies, including the effects of immunomodulatory derivatives on blood cell production pathways and the role of inflammatory mediators in immune system dysfunction. Additionally, they will discuss the development of vaccines targeting p...
A new study finds that vismodegib, a hedgehog pathway inhibitor, prevents the development of advanced basal cell carcinomas in patients with basal cell nevus syndrome. The treatment also shows promise for patients with an inherited predisposition to basal cell carcinoma.
Cancer cells that reign during leukemia relapses have distinct DNA profiles compared to those at diagnosis. These mutated cells exhibit aggressive behavior in mice, suggesting a possible link between human and mouse models.
A new hedgehog pathway inhibitor, GDC-0449, demonstrated efficacy in preventing and treating basal cell cancer among patients with basal cell nevus syndrome. The drug reduced the development of new lesions and decreased tumor size, offering a promising treatment option for these patients.
Forced splicing of p21Cip1 gene leads to its down-regulation and induction of programmed cell death in cancer cells. This finding suggests new approaches to enhance chemotherapeutic drug efficacy by inhibiting splicing.
PBS-Bio presents two abstracts at the AACR conference, showing how drugs UNBS1450 and NDC-1308 affect cancer cells. The technology allows real-time measurement of cellular responses to drugs, identifying potential biomarkers for patient selection and drug development.
A recent study published in the Journal of Thoracic Oncology found that soy isoflavones can sensitize cancer cells to radiation, increasing killing efficiency while protecting normal lung tissue from damage. Researchers used a soy mixture consisting of genistein, daidzein and glycitein to demonstrate this effect.
Researchers at Dana-Farber Cancer Institute have developed a targeted therapy strategy that slows the progression of NUT midline carcinoma in children. The approach uses an HDAC inhibitor to distract cancer proteins from their usual activity, causing cells to behave like normal cells.
A study identified three critical steps to transform normal blood cells into leukaemic ones, each subverting a different cellular process. The researchers found that NPM1 mutation is a key event in acute myeloid leukaemia development and can cooperate with other mutations to cause the disease.
Researchers at LSU Health Sciences Center have identified a protein called c-MYC oncoprotein that enables cancer cells to resist DNA-damaging agents like cisplatin. The study suggests that inhibiting this protein may provide a novel strategy for cancer therapy in combination with DNA-damaging agents.
Researchers created a computational model that describes how intestinal cells in mice respond to TNF, revealing the importance of location and protein interactions in cell fate. The study demonstrates the power of systems biology in modeling complex biological systems and predicting disease outcomes.
A Cardiff University-led study has discovered a protein, calmodulin, that protects pancreatic cells against the harmful effects of alcohol. The findings could lead to the development of new treatments for pancreatitis and reduce the risk of pancreatic cancer.
A Purdue University scientist has developed a nanopolymer that can detect the effectiveness of cancer drugs against biochemical processes leading to cancer cell formation. This innovation could replace radioisotopes and antibodies in screening kinase inhibitors, making it a universal method for pharmaceuticals.
Researchers found that MeSeCys killed more lung cancer cells than SeMet, which may explain conflicting results on selenium's health benefits. The study could provide insight into the chemopreventive properties of different selenium forms.
The authors refine the original six hallmarks using information from transgenic animals and biochemical assays, adding two new categories: enabling characteristics and emerging hallmarks. This updated review provides a solid basis for cancer research and identifies therapeutic targets.
Scientists have identified a distinct group of effector regulatory T cells responsible for suppressing immune responses. The discovery has significant repercussions for the treatment of autoimmune diseases, organ transplantation, and cancer, as well as how the efficacy of newly developed drugs is measured.
Researchers have synthesized cancer literature to introduce the concept of enabling and emerging hallmarks, which are features that set the stage for cancer and may become core characteristics in nearly all cancers. This review article provides a cohesive foundation for biomedical researchers to develop new cancer treatments.
Researchers at NIST and NCI have developed a technique that slices off the top of a cell, making structures accessible for spectroscopic examination. This allows for chemical mapping of cells at submicrometer resolution, potentially enabling early detection of cancer.
Researchers at Arizona State University have received a $1 million grant to develop a next-generation 3D imaging microscope called Cell-CT. This technology enables scientists to observe and assess the functional pathways of disease, such as cancer, by performing CT imaging on individual living cells.
A new study reveals that the CCCTC-binding factor (CTCF) and BORIS proteins directly regulate Rb2/p130 gene expression in lung cells. The findings show that small lung cancer cells exhibit low expression levels of Rb2/p130, while non-small lung cancer cells are overexpressed compared to normal lung cells.
Researchers at Trinity College Dublin have discovered how autophagy, a process of 'self-eating', safeguards against cancer development. The discovery highlights an unexpected role for Noxa in triggering the self-destructive process that kills fledgling tumour cells.
Research team designed synthetic molecules to study proline residue's role in cancer cell apoptosis by XIAP protein. The results suggest that these tetrapeptide analogs can be further developed into new molecular tools to analyze protein-protein interactions and signal transduction pathways of XIAP in cancer cells.
A recent study published in PLOS Biology reveals that Break-induced Replication (BIR) is up to 2,800 times more likely to cause genetic mutations than normal DNA synthesis. The researchers found that this method of DNA repair can lead to sudden bursts of mutagenesis, increasing the risk of cancerous cell development.
Researchers have discovered a compound, ABT-737, that sensitizes hypoxic cancer cells to apoptosis. This compound synergizes with conventional chemotherapeutic agents in tumor-bearing mice, suggesting improved treatment of solid tumors.
UBE4B is a molecule that binds to p53 and MDM2, allowing them to degrade the tumor-suppressing protein p53 in cancer cells. This discovery could lead to novel anti-cancer therapies and improve prognosis for cancer patients.
Scientists at VCU Massey Cancer Center have developed a novel treatment strategy for multiple myeloma that pairs two targeted agents to kill cancer cells. The combination regimen of Src inhibitors and Chk1 inhibitors induces cell death in multiple myeloma cells while sparing healthy cells.
Researchers propose cancer cells employ ancient genetic pathways, a 'toolkit' from 1 billion years ago, to evade control and develop resistance. This concept offers new hope for personalized medicine and potentially reveals clues about life's history.
Scientists discovered how stressed cells boost thrombin production, a key blood-clotting factor, which may be taken advantage by cancer cells. This process could explain why cancer patients are more likely to suffer from blood clots and septicaemia.
Scientists at Georgia Institute of Technology have found a regulatory RNA called miR-429 that can induce metastatic cancer cells to convert back into less invasive forms. This discovery may allow physicians to treat ovarian cancer more effectively with traditional chemotherapy.
Five scientists with novel approaches to fighting cancer have been awarded the Damon Runyon-Rachleff Innovation Award, receiving a total of $2.25 million over three years. The recipients aim to significantly impact cancer prevention, diagnosis, and treatment through their pioneering ideas.
Researchers at Duke University Medical Center discovered that genetic mutations in brain tumors can alter their metabolism. This study found over 100 metabolites with altered concentrations in cells with the defective IDH1 or IDH2 genes, providing promising avenues for future research into new treatments.
Researchers are developing a new method to identify cell abnormalities, including cancer, by analyzing the shape and behavior of individual cells. They have created mathematical equations that describe cell appearance and motion, which could be used to gauge future stages of a disease.
Researchers have identified a link between mitochondrial fusion and a cell death pathway, with implications for treating heart disease and stroke. The study found that the proteins MFN1 and MFN2 regulate mitochondrial behavior, promoting or preventing apoptosis, depending on their combination.
A team of researchers has made a discovery about how the Ras oncogene chooses a signaling pathway and its consequences in cellular development, a key issue in cancer. The study used a common roundworm, C. elegans, to identify the critical events leading to pancreatic cancer.
Researchers found that endothelial cells lining blood vessels secrete molecules suppressing tumor growth and invasion. The discovery could lead to a new way to treat cancer by implanting these cells adjacent to the tumor.
Researchers identified a chaperone enzyme, Rad18, that plays a key role in accurate DNA repair, and a signaling protein, Cdc7, that ensures error-free repair. This discovery offers a promising new target for cancer therapies, potentially overcoming resistance to DNA-damaging treatments.
Scientists discover a pro-survival mechanism in skin cancer cells, which may lead to new therapeutic targets. Researchers also develop a method to generate hyaline cartilage using adult skin cells.
Researchers discover that PML limits cancer cell division, and its absence allows tumors to grow uncontrollably. The presence of PML molecules can be detected, enabling diagnosis of malignant tumors.
Researchers found that estrogen induces the expression of CYP1B1 enzyme in precancerous cells, which promotes their movement and division. Depleting CYP1B1 reduces cell mobility and death in precancerous cells.
Researchers developed a device using angle-resolved low coherence interferometry to detect pre-cancerous cells in the esophagus lining. The technology holds promise for earlier detection and targeted biopsies, potentially improving treatment outcomes for esophageal cancer.
Researchers at Duke Cancer Institute discover a way to prevent the development of invadopodia structures that enable cancer cells to spread. By blocking Abl and Arg kinases, they also eliminate protein function that burns through tissue, allowing cancer cells to enter new cells.
Researchers used zebrafish to track the behavior of cancer cells and immune cells, discovering that cancer cells produce hydrogen peroxide to attract immune cells. This co-option of the immune system allows tumors to grow and spread, but blocking this interaction can prevent tumor formation.
Researchers at TUM have developed a new mechanism for reversible proteasome inhibition, which could lead to improved treatments for cancer and immune reactions. By targeting the immuno-proteasome specifically, they aim to minimize damage caused by side effects.
Researchers identified pomegranate juice components that inhibit the movement of cancer cells and weaken their attraction to a chemical signal. The effects of these components on prostate cancer progression are still controversial and require further testing.
Researchers found that adding ipilimumab to paclitaxel/carboplatin improved progression-free survival rates for stage IIIb/IV non-small cell lung cancer patients. The study suggests that ipilimumab may be a valuable addition to standard treatments, potentially leading to better patient outcomes.